GALERA THERAPEUTICS, INC.

Analyst Reco. Galera Therapeutics, Inc.

Equities

GRTX

US36338D1081

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
0.173 ^USD	-6.99%		-5.26%	+18.98%

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Mar. 28	Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Galera Therapeutics to Neutral From Buy, Adjusts Price Target to $0.30 From $6	23-08-16	MT
Piper Sandler Downgrades Galera Therapeutics to Neutral From Overweight, Adjusts Price Target to $0.50 From $6	23-08-10	MT
HC Wainwright Adjusts Galera Therapeutics Price Target to $6 From $10, Maintains Buy Rating	23-03-22	MT
Piper Sandler Starts Galera Therapeutics at Overweight With $6 Price Target	23-02-21	MT
BofA Securities Upgrades Galera Therapeutics to Buy From Underperform, Adjusts Price Target to $7 From $2	23-02-16	MT
BofA Securities Downgrades Galera Therapeutics to Underperform From Neutral, Sets Price Target at $2	22-05-27	MT
Citigroup Adjusts Galera Therapeutics' Price Target to $20 From $11, Reiterates Buy Rating	21-12-20	MT
HC Wainwright Upgrades Galera Therapeutics to Buy From Neutral; Price Target is $10	21-12-15	MT
BofA Securities Upgrades Galera Therapeutics to Neutral From Underperform, Adjusts Price Target to $4 From $2	21-12-15	MT
BTIG Upgrades Galera Therapeutics to Buy From Neutral; Price Target is $15	21-12-15	MT
Galera Therapeutics Extends Gains in Pre-Market Following Ratings Upgrades from BTIG, BofA Securities	21-12-15	MT
Today on Wall Street: Earnings season, bitcoin and the metaverse	21-10-20
GALERA THERAPEUTICS : HC Wainwright Downgrades Galera Therapeutics to Neutral From Buy	21-10-20	MT
ANALYST RECOMMENDATIONS : BHP Group, Cloudflare, Tesla, Microsoft, Target...	21-10-20
GALERA THERAPEUTICS : BTIG Downgrades Galera Therapeutics to Neutral from Buy	21-10-19	MT
GALERA THERAPEUTICS : Credit Suisse Upgrades Galera Therapeutics to Outperform from Neutral on Positive Proof of Concept Data, Adjusts Price Target to $15 from $9	20-12-16	MT
GALERA THERAPEUTICS : Credit Suisse Upgrades Galera Therapeutics to Outperform From Neutral, Adjusts Price Target to $15 From $9	20-12-16	MT
GALERA THERAPEUTICS : HC Wainwright Starts Galera Therapeutics at Buy With $15 Price Target	20-12-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW